Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, HUB Hôpital Erasme, Université Libre de Bruxelles, Brussels Belgium.
Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.
Acta Gastroenterol Belg. 2024 Apr-Jun;87(2):263-273. doi: 10.51821/87.2.12805.
Previous history of COVID-19 infection is a natural booster of the vaccine response in the general population. The response to COVID-19 vaccines is lessened in Inflammatory Bowel Disease patients on selected class of immunosuppressive treatments.
The study was to assess anti-SARS-CoV-2 spike-specific IgG antibody response in Inflammatory Bowel Disease patients with a history of COVID-19 infection.
This single-center prospective study involved 504 Inflammatory Bowel Disease patients. Demographic data and clinical data were gathered through questionnaires and patient charts. Anti-SARS-CoV-2 spike-specific and antinucleocapsid antibody levels were measured at T1, T2 (after the 2-dose series), and T3 or T4 (booster vaccine).
This study included 504 Inflammatory Bowel Disease patients, and 234 completed one year follow-up with blood tests. Positive anti-nucleocapsid serology or history of COVID-19 infection was significantly associated with increased median anti- SARS-CoV-2 spike-specific IgG titers after the 2-dose series (1930 BAU/mL vs. 521 BAU/mL p < 0.0001) and the booster vaccine (4390 BAU/mL vs. 2160 BAU/mL, p = 0.0156). Multivariate analysis showed that higher anti-SARS-CoV-2 spike-specific IgG levels were independently associated with anti-nucleocapsid antibodies at T2 (OR=2.23, p < 0.0001) and T3 (OR=1.72, p = 0.00011). Immunosuppressive treatments did not impact the antibody response or levels in patients with a history of COVID-19 infection or positive anti-nucleocapsid serology.
In Inflammatory Bowel Disease, prior COVID-19 infection or positive anti-nucleocapsid serology leads to increased anti-SARS-CoV-2 spike-specific IgG levels after vaccination, regardless of immunosuppressive treatments. This emphasizes the significance of accounting for previous infection in vaccination approaches.
先前的 COVID-19 感染史是普通人群中疫苗反应的自然增强剂。在接受特定类别的免疫抑制治疗的炎症性肠病患者中，COVID-19 疫苗的反应会减弱。
本研究旨在评估有 COVID-19 感染史的炎症性肠病患者对 SARS-CoV-2 刺突特异性 IgG 抗体的反应。
这是一项单中心前瞻性研究，共纳入 504 例炎症性肠病患者。通过问卷和患者病历收集人口统计学数据和临床数据。在 T1、T2（两剂系列后）和 T3 或 T4（加强疫苗）时测量抗 SARS-CoV-2 刺突特异性和抗核衣壳抗体水平。
本研究纳入了 504 例炎症性肠病患者，其中 234 例完成了一年的随访和血液检查。抗核衣壳血清学阳性或 COVID-19 感染史与两剂系列后 SARS-CoV-2 刺突特异性 IgG 滴度升高显著相关（1930 BAU/mL 与 521 BAU/mL，p < 0.0001）和加强疫苗（4390 BAU/mL 与 2160 BAU/mL，p = 0.0156）。多变量分析显示，T2（OR=2.23，p < 0.0001）和 T3（OR=1.72，p = 0.00011）时更高的抗 SARS-CoV-2 刺突特异性 IgG 水平与抗核衣壳抗体独立相关。免疫抑制治疗并未影响有 COVID-19 感染史或抗核衣壳血清学阳性患者的抗体反应或水平。
在炎症性肠病中，先前的 COVID-19 感染或抗核衣壳血清学阳性导致接种疫苗后 SARS-CoV-2 刺突特异性 IgG 水平升高，无论免疫抑制治疗如何。这强调了在疫苗接种方法中考虑既往感染的重要性。
